Ryu WonHyoung, Huang Zhinong, Prinz Fritz B, Goodman Stuart B, Fasching Rainer
Rapid Prototyping Laboratory, Mechanical Engineering Department, 440 Escondido Mall, Bldg. 530, Rm 226, Stanford University, Stanford, CA 94305, USA.
J Control Release. 2007 Dec 4;124(1-2):98-105. doi: 10.1016/j.jconrel.2007.08.024. Epub 2007 Aug 25.
Microelectromechanical system (MEMS) technology not only provides the possibility of integration of multiple functions but also enables more precise control of dosing of therapeutic agents when the therapeutic window is very limited. Local delivery of basic fibroblast growth factor (bFGF) over a specific dose and time course is critical for mesenchymal tissue regeneration. However, bFGF is degraded quickly in vivo and difficulty of controlling the dose level impedes its effective use in angiogenesis and tissue regeneration. We constructed biodegradable micro-osmotic pumps based on MEMS technology for long-term controlled release of bFGF. The devices were constructed by micro-molding and thermal assembly of 85/15 poly(L-lactide-co-glycolide) sheets. The release of bFGF was regulated at 40 ng/day for four weeks; bioactivity was assessed by monitoring the growth of 3T3 fibroblasts. The proposed devices can be further miniaturized and used for the delivery of multiple therapeutic agents at the individual releasing schedules.
微机电系统(MEMS)技术不仅提供了集成多种功能的可能性,而且当治疗窗口非常有限时,还能实现对治疗剂给药更精确的控制。在特定剂量和时间过程中局部递送碱性成纤维细胞生长因子(bFGF)对于间充质组织再生至关重要。然而,bFGF在体内会迅速降解,并且控制剂量水平的困难阻碍了其在血管生成和组织再生中的有效应用。我们基于MEMS技术构建了可生物降解的微渗透泵,用于bFGF的长期控释。这些装置通过对85/15聚(L-丙交酯-共-乙交酯)片材进行微成型和热组装来构建。bFGF的释放被调节为在四周内每天40纳克;通过监测3T3成纤维细胞的生长来评估生物活性。所提出的装置可以进一步小型化,并用于按照个体释放时间表递送多种治疗剂。